Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Amortization of Deferred Charges (2020 - 2025)

Kymera Therapeutics (KYMR) has disclosed Amortization of Deferred Charges for 6 consecutive years, with -$2.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Amortization of Deferred Charges rose 37.4% to -$2.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$8.9 million, a 36.5% increase, with the full-year FY2025 number at -$8.9 million, up 36.5% from a year prior.
  • Amortization of Deferred Charges was -$2.0 million for Q4 2025 at Kymera Therapeutics, up from -$2.2 million in the prior quarter.
  • In the past five years, Amortization of Deferred Charges ranged from a high of $1.7 million in Q3 2021 to a low of -$4.0 million in Q2 2024.
  • A 5-year average of -$1.1 million and a median of -$1.3 million in 2023 define the central range for Amortization of Deferred Charges.
  • Peak YoY movement for Amortization of Deferred Charges: tumbled 1998.28% in 2023, then soared 47.25% in 2025.
  • Kymera Therapeutics' Amortization of Deferred Charges stood at $1.6 million in 2021, then tumbled by 155.32% to -$905000.0 in 2022, then plummeted by 40.22% to -$1.3 million in 2023, then plummeted by 157.45% to -$3.3 million in 2024, then surged by 37.4% to -$2.0 million in 2025.
  • Per Business Quant, the three most recent readings for KYMR's Amortization of Deferred Charges are -$2.0 million (Q4 2025), -$2.2 million (Q3 2025), and -$2.1 million (Q2 2025).